A Phase 3, Randomized Study Evaluating the Efficacy and Safety of NDV-01 Versus Observation in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (BOOST)
Latest Information Update: 06 Jan 2026
At a glance
- Drugs Docetaxel/gemcitabine (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms BOOST
- Sponsors Relmada Therapeutics
Most Recent Events
- 02 Jan 2026 Status changed from planning to not yet recruiting.
- 15 Dec 2025 New trial record
- 13 Nov 2025 According to a Relmada Therapeutics media release, the company look forward to working with the FDA to establish the final study design and initiate the registrational program in the first half of 2026.